Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development

Magdalena Ślusarczyk(Cardiff University), Christopher McGuigan(University College Dublin), Jan Balzarini, Sarah P. Blagden(Churchill Hospital), Monica Huerta Lopez(Cardiff University), Emely Thompson(Queen Mary University of London), Essam Ghazaly(Queen Mary University of London), Wen G. Jiang(Shandong Center for Disease Control and Prevention), Malcolm D. Mason(Royal Marsden Hospital)
Journal of Medicinal Chemistry
January 28, 2014
10.1021/jm401853a
Cited by 151

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
|Clinical Cancer Research|2011|168